Reuters logo
BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD
September 20, 2017 / 11:30 AM / 3 months ago

BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

Sept 20 (Reuters) - Regenxbio Inc:

* Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

* Regenxbio Inc - ‍ plans to share an interim trial update for Phase I clinical trial of RGX-314 by end of 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below